Citations (121)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Guru R. Valicherla, Amrut Mishra, Srinivas Lenkalapelly, Bhupathi Jillela, Femi M. Francis, Lakshman Rajagopalan & Pratima Srivastava. (2019) Investigation of the inhibition of eight major human cytochrome P450 isozymes by a probe substrate cocktail in vitro with emphasis on CYP2E1. Xenobiotica 49:12, pages 1396-1402.
Read now
Read now
Yannick Parmentier, Corinne Pothier, Nicola Hewitt, Ludwig Vincent, Fabrice Caradec, Jia Liu, Feifei Lin, Marie-Michèle Trancart, Fabrice Guillet, Belkacem Bouaita, Christophe Chesne & Bernard Walther. (2019) Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model. Xenobiotica 49:1, pages 22-35.
Read now
Read now
Robert M Levy, Lakshmi Pillai & Bruce P Burnett. (2010) Nutritional benefits of flavocoxid in patients with osteoarthritis: efficacy and safety. Nutrition and Dietary Supplements 2, pages 27-38.
Read now
Read now
Petri Reponen, Khaled Abass, Sampo Mattila & Olavi Pelkonen. (2010) Overview of the metabolism and interactions of pesticides in hepatic in vitro systems. International Journal of Environmental Analytical Chemistry 90:3-6, pages 429-437.
Read now
Read now
James J Cali, Andrew Niles, Michael P Valley, Martha A O'Brien, Terry L Riss & John Shultz. (2008) Bioluminescent assays for ADMET. Expert Opinion on Drug Metabolism & Toxicology 4:1, pages 103-120.
Read now
Read now
O. Pelkonen & M. Turpeinen. (2007) extrapolation of hepatic clearance: Biological tools, scaling factors, model assumptions and correct concentrations. Xenobiotica 37:10-11, pages 1066-1089.
Read now
Read now
Thomas M Polasek & John O Miners. (2007) In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opinion on Drug Metabolism & Toxicology 3:3, pages 321-329.
Read now
Read now
Jan L Wahlstrom, Dan A Rock, J Greg Slatter & Larry C Wienkers. (2006) Advances in predicting CYP-mediated drug interactions in the drug discovery setting. Expert Opinion on Drug Discovery 1:7, pages 677-691.
Read now
Read now
James J Cali, Dongping Ma, Mary Sobol, Daniel J Simpson, Susan Frackman, Troy D Good, William J Daily & David Liu. (2006) Luminogenic cytochrome P450 assays. Expert Opinion on Drug Metabolism & Toxicology 2:4, pages 629-645.
Read now
Read now
M. G. Soars, K. Grime & R. J. Riley. (2006) Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica 36:4, pages 287-299.
Read now
Read now
K. H. Liu, M. J. Kim, J. H. Shon, Y. S. Moon, S. Y. Seol, W Kang, I. J. Cha & J. G. Shin. (2005) Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. Xenobiotica 35:1, pages 27-38.
Read now
Read now
M. Jane Cox Rosemond & John S. Walsh. (2004) Human Carbonyl Reduction Pathways and a Strategy for Their Study In Vitro. Drug Metabolism Reviews 36:2, pages 335-361.
Read now
Read now
T. Yamamoto, A. Suzuki & Y. Kohno. (2004) High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method. Xenobiotica 34:1, pages 87-101.
Read now
Read now
M. N. V. S. Rao, B. Biju, A. K. Ansar, S. Mujeeb, M. Ramesh & N. R. Srinivas. (2003) ‘Open access’ generic method for continuous determination of major human CYP450 probe substrates/metabolites and its application in drug metabolism studies. Xenobiotica 33:12, pages 1233-1245.
Read now
Read now
Manoj Bajpai & Joel D. Esmay. (2002) IN VITRO STUDIES IN DRUG DISCOVERY AND DEVELOPMENT: AN ANALYSIS OF STUDY OBJECTIVES AND APPLICATION OF GOOD LABORATORY PRACTICES (GLP). Drug Metabolism Reviews 34:4, pages 679-689.
Read now
Read now
N. Hagen, A. K. Olsen, J. V. Andersen, J. Tjørnelund & S. H. Hansen. (2002) Characterization of mixtures of recombinant human cytochrome P450s as a screening model for metabolic stability in drug discovery. Xenobiotica 32:9, pages 749-759.
Read now
Read now
S. F. Zhou, M. D. Tingle, P. Kestell & J. W. Paxton. (2002) Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro : implications for prediction of metabolic interactions in vivo. Xenobiotica 32:2, pages 87-107.
Read now
Read now
S. A. Roberts. (2001) High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica 31:8-9, pages 557-589.
Read now
Read now
H. Yin, J. Racha, S.-Y. Li, N. Olejnik, H. Satoh & D. Moore. (2000) Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation. Xenobiotica 30:2, pages 141-154.
Read now
Read now
Articles from other publishers (102)
Stefano Fontana, Simone Braggio, Mauro Corsi, Rob Riley, Chris Strock, Jenifer Bradley, Caterina Virginio & Paul Walker. 2023. The Handbook of Medicinal Chemistry. The Handbook of Medicinal Chemistry
533
596
.
Yi Hsiao, Bo-Han Su & Yufeng J Tseng. (2021) Current development of integrated web servers for preclinical safety and pharmacokinetics assessments in drug development. Briefings in Bioinformatics 22:3.
Crossref
Crossref
Li Di, Amanda Balesano, Samantha Jordan & Sophia M. Shi. (2021) The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation. The AAPS Journal 23:1.
Crossref
Crossref
Jasleen K. Sodhi & Jason S. Halladay. 2021. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
765
779
.
Slobodan Rendic & Frederick Peter Guengerich. (2020) Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters. Current Drug Metabolism 21:14, pages 1127-1135.
Crossref
Crossref
Hugues Chanteux, Maria Rosa, Claude Delatour, Johan Nicolaï, Eric Gillent, Sylvie Dell’Aiera & Anna-Lena Ungell. (2020) Application of Azamulin to Determine the Contribution of CYP3A4/5 to Drug Metabolic Clearance Using Human Hepatocytes. Drug Metabolism and Disposition 48:9, pages 778-787.
Crossref
Crossref
Y.F. Yong, S.C. Tan, Mervyn W.O. Liew & N.S. Yaacob. (2020) Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method development for screening of potential tamoxifen-drug/herb interaction via in vitro cytochrome P450 inhibition assay. Journal of Chromatography B 1148, pages 122148.
Crossref
Crossref
Chen Shi, Qian Wang, Xuemei Liao, Hui Ge, Guoyong Huo, Leduo Zhang, Na Chen, Xiong Zhai, Yuan Hong, Li Wang, Zhe Wang, Weijun Shi, Yu Mao, Jianxin Yu, Ying Ke & Guangxin Xia. (2020) Discovery of a novel series of imidazo[1′,2’:1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors. European Journal of Medicinal Chemistry 193, pages 112239.
Crossref
Crossref
Adrian J. Fretland, Tashinga E. Bapiro, Barry Jones, Roshini Markandu, Alexandra L. Orton & Venkatesh Pilla Reddy. 2020. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters
213
236
.
Chen Shi, Qian Wang, Xuemei Liao, Hui Ge, Guoyong Huo, Leduo Zhang, Na Chen, Xiong Zhai, Yuan Hong, Li Wang, Yanan Han, Wenbo Xiao, Zhe Wang, Weijun Shi, Yu Mao, Jianxin Yu, Guangxin Xia & Yanjun Liu. (2019) Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer. European Journal of Medicinal Chemistry 178, pages 352-364.
Crossref
Crossref
Vinay R. Sonawane, Mohd Usman Mohd Siddique, Linda Gatchie, Ibidapo S. Williams, Sandip B. Bharate, Venkatesan Jayaprakash, Barij N. Sinha & Bhabatosh Chaudhuri. (2019) CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance. European Journal of Pharmaceutical Sciences 131, pages 177-194.
Crossref
Crossref
Paul Quantin, Elodie Colaço, Karim El Kirat, Christophe Egles, Hervé Ficheux & Jessem Landoulsi. (2018) Layer-by-Layer Assembly of Nanosized Membrane Fractions for the Assessment of Cytochrome P450 Xenobiotic Metabolism. ACS Omega 3:10, pages 12535-12544.
Crossref
Crossref
Chien‐Wei Chiang, Pengyue Zhang, Xueying Wang, Lei Wang, Shijun Zhang, Xia Ning, Li Shen, Sara K. Quinney & Lang Li. (2017) Translational High‐Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models. Clinical Pharmacology & Therapeutics 103:2, pages 287-295.
Crossref
Crossref
Snehasis Jana & Himanshu Rastogi. (2017) Effects of Caffeic Acid and Quercetin on In Vitro Permeability, Metabolism and In Vivo Pharmacokinetics of Melatonin in Rats: Potential for Herb-Drug Interaction. European Journal of Drug Metabolism and Pharmacokinetics 42:5, pages 781-791.
Crossref
Crossref
Deyan Wu, Tianhua Zhang, Yiping Chen, Yadan Huang, Haiju Geng, Yanfa Yu, Chen Zhang, Zengwei Lai, Yinuo Wu, Xiaolei Guo, Jianwen Chen & Hai-Bin Luo. (2017)
Discovery and Optimization of Chromeno[2,3-
c
]pyrrol-9(2
H
)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension
. Journal of Medicinal Chemistry 60:15, pages 6622-6637.
Crossref
Crossref
Solomon Tadesse, Mingfeng Yu, Laychiluh B. Mekonnen, Frankie Lam, Saiful Islam, Khamis Tomusange, Muhammed H. Rahaman, Benjamin Noll, Sunita K. C. Basnet, Theodosia Teo, Hugo Albrecht, Robert Milne & Shudong Wang. (2017)
Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-
N
-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation
. Journal of Medicinal Chemistry 60:5, pages 1892-1915.
Crossref
Crossref
Y Shirasaka, A S Chaudhry, M McDonald, B Prasad, T Wong, J C Calamia, A Fohner, T A Thornton, N Isoherranen, J D Unadkat, A E Rettie, E G Schuetz & K E Thummel. (2015) Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. The Pharmacogenomics Journal 16:4, pages 375-387.
Crossref
Crossref
Chong‐Zhen Qin, Xian Ren, Zhi‐Rong Tan, Yao Chen, Ji‐Ye Yin, Jing Yu, Jian Qu, Hong‐Hao Zhou & Zhao‐Qian Liu. (2013)
A high‐throughput inhibition screening of major human cytochrome P450 enzymes using an
in vitro
cocktail and liquid chromatography–tandem mass spectrometry
. Biomedical Chromatography 28:2, pages 197-203.
Crossref
Crossref
Gary W. Caldwell & Zhengyin Yan. 2014. Optimization in Drug Discovery. Optimization in Drug Discovery
315
336
.
Gary W. Caldwell & Zhengyin Yan. 2014. Optimization in Drug Discovery. Optimization in Drug Discovery
281
303
.
Xiao-Mei Zhuang, Yu-Huan Zhong, Wei-Bin Xiao, Hua Li & Chuang Lu. (2013) Identification and Characterization of Psoralen and Isopsoralen as Potent CYP1A2 Reversible and Time-Dependent Inhibitors in Human and Rat Preclinical Studies. Drug Metabolism and Disposition 41:11, pages 1914-1922.
Crossref
Crossref
Jörg Fabian, Walburga Hanekamp, Mélanie H. Thomas, Jean Luc Olivier & Matthias Lehr. (2013) Investigations on the metabolic stability of cytosolic phospholipase A2α inhibitors with 1-indolylpropan-2-one structure. Chemico-Biological Interactions 206:2, pages 356-363.
Crossref
Crossref
Dhanuka P. Wasalathanthri, Spundana Malla, Itti Bist, Chi K. Tang, Ronaldo C. Faria & James F. Rusling. (2013) High-throughput metabolic genotoxicity screening with a fluidic microwell chip and electrochemiluminescence. Lab on a Chip 13:23, pages 4554.
Crossref
Crossref
Geoffrey Holdgate, Stefan Geschwindner, Alex Breeze, Gareth Davies, Nicola Colclough, David Temesi & Lara Ward. 2013. Protein-Ligand Interactions. Protein-Ligand Interactions
327
355
.
Alexander V. LyubimovPeter L. Bullock & Olga V. Trubetskoy. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
26
.
Alexander V. LyubimovHiroshi Komura & Masahiro Iwaki. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
41
.
Sheila J. Sadeghi, Silvia Ferrero, Giovanna Di Nardo & Gianfranco Gilardi. (2012) Drug–drug interactions and cooperative effects detected in electrochemically driven human cytochrome P450 3A4. Bioelectrochemistry 86, pages 87-91.
Crossref
Crossref
Ming Yao, Hong Cai & Mingshe Zhu. 2012. ADME‐Enabling Technologies in Drug Design and Development. ADME‐Enabling Technologies in Drug Design and Development
213
232
.
Poncho L. Meisenheimer, H. Tetsuo Uyeda, Dongping Ma, Mary Sobol, Mark G. McDougall, Cesear Corona, Dan Simpson, Dieter H. Klaubert & James J. Cali. (2011) Proluciferin Acetals as Bioluminogenic Substrates for Cytochrome P450 Activity and Probes for CYP3A Inhibition. Drug Metabolism and Disposition 39:12, pages 2403-2410.
Crossref
Crossref
Siamak Cyrus Khojasteh, Saileta Prabhu, Jane R. Kenny, Jason S. Halladay & Anthony Y. H. Lu. (2011) Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. European Journal of Drug Metabolism and Pharmacokinetics 36:1, pages 1-16.
Crossref
Crossref
Brad Larson, Peter Banks, James J. Cali, Mary Sobol & Sarah Shultz. (2011) Automated Luminescence-Based Cytochrome P450 Profiling Using a Simple, Elegant Robotic Platform. JALA: Journal of the Association for Laboratory Automation 16:1, pages 47-55.
Crossref
Crossref
Malini Dasgupta, Weimin Tang, Gary W. Caldwell & Zhengyin Yan. (2010) Use of stable isotope labeled probes to facilitate liquid chromatography/mass spectrometry based high‐throughput screening of time‐dependent CYP inhibitors. Rapid Communications in Mass Spectrometry 24:15, pages 2177-2185.
Crossref
Crossref
Jane R. Kenny, Dermot F. McGinnity, Ken Grime & Robert J. Riley. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
38
.
Olavi Pelkonen, Ari Tolonen, Miia Turpeinen & Jouko Uusitalo. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
32
.
Eugene G. Hrycay & Stelvio M. Bandiera. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
70
.
Brett A. Litten, Robin Smith & Eleanor Banfield. (2010) An Automated 1536-Well Microplate Format Cytochrome P450 Inhibition Assay Using a Tecan Freedom EVO Workstation with Integrated Innovadyne Nanodrop II Dispenser. JALA: Journal of the Association for Laboratory Automation 15:1, pages 58-64.
Crossref
Crossref
Ramesh B. Bambal & Stephen E. Clarke. 2009. Evaluation of Drug Candidates for Preclinical Development. Evaluation of Drug Candidates for Preclinical Development
55
107
.
Onur Dagliyan, I. Halil Kavakli & Metin Turkay. (2009)
Classification of Cytochrome P450 Inhibitors with Respect to Binding Free Energy and pIC
50
Using Common Molecular Descriptors
. Journal of Chemical Information and Modeling 49:10, pages 2403-2411.
Crossref
Crossref
Marcel J. de Groot, Florian Wakenhut, Gavin Whitlock & Ruth Hyland. (2009) Understanding CYP2D6 interactions. Drug Discovery Today 14:19-20, pages 964-972.
Crossref
Crossref
Ruth Hyland, R. Scott Obach, Chad Stoner, Michael West, Michael R. Wester, Kuresh Youdim & Michael Zientek. 2009. Hit and Lead Profiling. Hit and Lead Profiling
165
196
.
Stephen Fowler & Hongjian Zhang. (2008) In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and their Utility for Predicting Drug–Drug Interactions. The AAPS Journal 10:2, pages 410-424.
Crossref
Crossref
Dan Rock, Jan Wahlstrom & Larry Wienkers. 2008. Antitargets. Antitargets
195
246
.
Tominaga FUKAZAWAKanako YAJIMAYohei MIYAMOTO. (2008) Evaluation of Drug-drug Interaction Potential of Beraprost Sodium Mediated by P450 In Vitro. YAKUGAKU ZASSHI 128:10, pages 1459-1465.
Crossref
Crossref
Thomas M. Polasek & John O. Miners. (2007) Time‐dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants. British Journal of Clinical Pharmacology 65:1, pages 87-97.
Crossref
Crossref
BRUCE P. BURNETT, STACIA SILVA, MICHAEL H. MESCHES, STEVEN WILSON & QI JIA. (2007) SAFETY EVALUATION OF A COMBINATION, DEFINED EXTRACT OF SCUTELLARIA BAICALENSIS AND ACACIA CATECHU. Journal of Food Biochemistry 31:6, pages 797-825.
Crossref
Crossref
Alexandre Olry, Florence Schneider‐Belhaddad, Dimitri Heintz & Danièle Werck‐Reichhart. (2007) A medium‐throughput screening assay to determine catalytic activities of oxygen‐consuming enzymes: a new tool for functional characterization of cytochrome P450 and other oxygenases. The Plant Journal 51:2, pages 331-340.
Crossref
Crossref
Ming Yao, Mingshe Zhu, Michael W. Sinz, Hongjian Zhang, W. Griffith Humphreys, A. David Rodrigues & Renke Dai. (2007) Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC–MS/MS analysis. Journal of Pharmaceutical and Biomedical Analysis 44:1, pages 211-223.
Crossref
Crossref
María José Gómez-Lechón, José Vicente Castell & María Teresa Donato. (2007) Hepatocytes—the choice to investigate drug metabolism and toxicity in man: In vitro variability as a reflection of in vivo. Chemico-Biological Interactions 168:1, pages 30-50.
Crossref
Crossref
Fan He, Hui‐chang Bi, Zhi‐yong Xie, Zhong Zuo, Jian‐kang Li, Xin Li, Li‐zi Zhao, Xiao Chen & Min Huang. (2007) Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high‐throughput inhibition screening of terpenoids. Rapid Communications in Mass Spectrometry 21:5, pages 635-643.
Crossref
Crossref
Ben-Fillippo Krippendorff, Philip Lienau, Andreas Reichel & Wilhelm Huisinga. (2007) Optimizing Classification of Drug-Drug Interaction Potential for CYP450 Isoenzyme Inhibition Assays in Early Drug Discovery. SLAS Discovery 12:1, pages 92-99.
Crossref
Crossref
Richard T. Mayer, E. Kurt Dolence & Gabriele E. Mayer. (2007)
A Real-Time Fluorescence Assay for Measuring
N
-Dealkylation
. Drug Metabolism and Disposition 35:1, pages 103-109.
Crossref
Crossref
Dermot F. McGinnity, James Tucker, Steve Trigg & Robert J. Riley. (2005) PREDICTION OF CYP2C9-MEDIATED DRUG-DRUG INTERACTIONS: A COMPARISON USING DATA FROM RECOMBINANT ENZYMES AND HUMAN HEPATOCYTES. Drug Metabolism and Disposition 33:11, pages 1700-1707.
Crossref
Crossref
Anthony Atkinson, Jane R. Kenny & Ken Grime. (2005) AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS. Drug Metabolism and Disposition 33:11, pages 1637-1647.
Crossref
Crossref
Gregor Zlokarnik, Peter D.J. Grootenhuis & John B. Watson. (2005) High throughput P450 inhibition screens in early drug discovery. Drug Discovery Today 10:21, pages 1443-1450.
Crossref
Crossref
Robert J. TurnerSteven J. Charlton. (2005)
Assessing the Minimum Number of Data Points Required for Accurate IC
50
Determination
. ASSAY and Drug Development Technologies 3:5, pages 525-531.
Crossref
Crossref
Larry C. Wienkers & Timothy G. Heath. (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nature Reviews Drug Discovery 4:10, pages 825-833.
Crossref
Crossref
Min‐Jung Kim, Hyojin Kim, In‐June Cha, Jang‐Su Park, Ji‐Hong Shon, Kwang‐Hyeon Liu & Jae‐Gook Shin. (2005)
High‐throughput screening of inhibitory potential of nine cytochrome P450 enzymes
in vitro
using liquid chromatography/tandem mass spectrometry
. Rapid Communications in Mass Spectrometry 19:18, pages 2651-2658.
Crossref
Crossref
Jan M. Kriegl, Thomas Arnhold, Bernd Beck & Thomas Fox. (2005) Prediction of Human Cytochrome P450 Inhibition Using Support Vector Machines. QSAR & Combinatorial Science 24:4, pages 491-502.
Crossref
Crossref
S. Bhoopathy, B. Xin, S.E. Unger & H.T. Karnes. (2005) A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes. Journal of Pharmaceutical and Biomedical Analysis 37:4, pages 739-749.
Crossref
Crossref
Jan M. Kriegl, Lennart Eriksson, Thomas Arnhold, Bernd Beck, Erik Johansson & Thomas Fox. (2005) Multivariate modeling of cytochrome P450 3A4 inhibition. European Journal of Pharmaceutical Sciences 24:5, pages 451-463.
Crossref
Crossref
Annalise Di Marco, Isabella Marcucci, Ashok Chaudhary, Marina Taliani & Ralph Laufer. (2005) DEVELOPMENT AND VALIDATION OF A HIGH-THROUGHPUT RADIOMETRIC CYP2C9 INHIBITION ASSAY USING TRITIATED DICLOFENAC. Drug Metabolism and Disposition 33:3, pages 359-364.
Crossref
Crossref
Annalise Di Marco, Isabella Marcucci, Maria Verdirame, José Pérez, Manuel Sanchez, Fernando Peláez, Ashok Chaudhary & Ralph Laufer. (2005) DEVELOPMENT AND VALIDATION OF A HIGH-THROUGHPUT RADIOMETRIC CYP3A4/5 INHIBITION ASSAY USING TRITIATED TESTOSTERONE. Drug Metabolism and Disposition 33:3, pages 349-358.
Crossref
Crossref
Mei-Fei Yueh, Marleen Kawahara & Judy Raucy. (2005) Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes. Toxicology in Vitro 19:2, pages 275-287.
Crossref
Crossref
Jan M. Kriegl, Thomas Arnhold, Bernd Beck & Thomas Fox. (2005) A support vector machine approach to classify human cytochrome P450 3A4 inhibitors. Journal of Computer-Aided Molecular Design 19:3, pages 189-201.
Crossref
Crossref
Olga V. Trubetskoy, Jasmin R. Gibson & Bryan D. Marks. (2005) Highly Miniaturized Formats for In Vitro Drug Metabolism Assays Using Vivid® Fluorescent Substrates and Recombinant Human Cytochrome P450 Enzymes. SLAS Discovery 10:1, pages 56-66.
Crossref
Crossref
Robert J. Riley & Ken Grime. (2004) Metabolic screening in vitro: metabolic stability, CYP inhibition and induction. Drug Discovery Today: Technologies 1:4, pages 365-372.
Crossref
Crossref
Dermot F. McGinnity, Matthew G. Soars, Richard A. Urbanowicz & Robert J. Riley. (2004) EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE. Drug Metabolism and Disposition 32:11, pages 1247-1253.
Crossref
Crossref
Matthias Unger & Andreas Frank. (2004) Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Communications in Mass Spectrometry 18:19, pages 2273-2281.
Crossref
Crossref
Kelly M. Jenkins, Reginald Angeles, Marianne T. Quintos, Rongda Xu, Daniel B. Kassel & Robyn A. Rourick. (2004) Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries. Journal of Pharmaceutical and Biomedical Analysis 34:5, pages 989-1004.
Crossref
Crossref
Lennart Eriksson, Thomas Arnhold, Bernd Beck, Thomas Fox, Erik Johansson & Jan M. Kriegl. (2004) Onion design and its application to a pharmaceutical QSAR problem. Journal of Chemometrics 18:3-4, pages 188-202.
Crossref
Crossref
John H. Ansede & Dhiren R. Thakker. (2004) High‐throughput screening for stability and inhibitory activity of compounds toward cytochrome P450‐mediated metabolism. Journal of Pharmaceutical Sciences 93:2, pages 239-255.
Crossref
Crossref
David M. Stresser, Marc I. Broudy, Thuy Ho, Catherine E. Cargill, Andrew P. Blanchard, Raman Sharma, Andre A. Dandeneau, Joseph J. Goodwin, Stephanie D. Turner, John C. L. Erve, Christopher J. Patten, Shangara S. Dehal & Charles L. Crespi. (2004) HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE. Drug Metabolism and Disposition 32:1, pages 105-112.
Crossref
Crossref
Annalise Di Marco, Dan Yao & Ralph Laufer. (2003) Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes. European Journal of Biochemistry 270:18, pages 3768-3777.
Crossref
Crossref
Jaime Padrós, Donald Chun, Liangfu Chen, Pierre Rigolli, Themis Flarakos & Mallé Jurima-Romet. (2003) A cell-based assay for screening the uridine 5′-diphosphate–glucuronosyltransferase 1A inhibitory potential of new chemical entities. Analytical Biochemistry 320:2, pages 310-312.
Crossref
Crossref
Richard Weaver, Ken S. Graham, Iain G. Beattie & Rob J. Riley. (2003) CYTOCHROME P450 INHIBITION USING RECOMBINANT PROTEINS AND MASS SPECTROMETRY/MULTIPLE REACTION MONITORING TECHNOLOGY IN A CASSETTE INCUBATION. Drug Metabolism and Disposition 31:7, pages 955-966.
Crossref
Crossref
Li Di & Edward H Kerns. (2003) Profiling drug-like properties in discovery research. Current Opinion in Chemical Biology 7:3, pages 402-408.
Crossref
Crossref
Balázs Dalmadi, János Leibinger, Szabolcs Szeberényi, Tı́mea Borbás, Sándor Farkas, Zsolt Szombathelyi & Károly Tihanyi. (2003) Identification of Metabolic Pathways Involved in the Biotransformation of Tolperisone by Human Microsomal Enzymes. Drug Metabolism and Disposition 31:5, pages 631-636.
Crossref
Crossref
Chongwoo Yu, Young Geun Shin, Jerome W. Kosmeder, John M. Pezzuto & Richard B. van Breemen. (2003) Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol‐3‐sulfate. Rapid Communications in Mass Spectrometry 17:4, pages 307-313.
Crossref
Crossref
Jagdish K. Racha, Z. Sylvia Zhao, Nicholas Olejnik, Nadine Warner, Rebecca Chan, David Moore & Hiroko Satoh. (2003) Substrate Dependent Inhibition Profiles of Fourteen Drugs on CYP3A4 Activity Measured by A High Throughput LCMS/MS Method with Four Probe Drugs, Midazolam, Testosterone, Nifedipine and Terfenadine. Drug Metabolism and Pharmacokinetics 18:2, pages 128-138.
Crossref
Crossref
Samuel A TestinoJr.Jr. & Gabor Patonay. (2003) High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography–tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 30:5, pages 1459-1467.
Crossref
Crossref
Shigeru Furuta, Nobuyoshi Akagawa, Emiko Kamada, Akio Hiyama, Yoshihiro Kawabata, Nobuhiko Kowata, Atsuhiro Inaba, Anne Matthews, Michael Hall & Tadashi Kurimoto. (2002) Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti‐inflammatory drug, and its lack of clinically significant CYP inhibition potential. British Journal of Clinical Pharmacology 54:3, pages 295-303.
Crossref
Crossref
Feng Gao, Diane L. Johnson, Sean Ekins, John Janiszewski, Kevin G. Kelly, R. Daniel Meyer & Michael West. (2002) Optimizing Higher Throughput Methods to Assess Drug–Drug Interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 In Vitro Using a Single Point IC50. SLAS Discovery 7:4, pages 373-382.
Crossref
Crossref
Ragu Ramanathan, Donald L. McKenzie, Meera Tugnait & Kristen Siebenaler. (2002) Application of semi-automated metabolite identification software in the drug discovery process for rapid identification of metabolites and the cytochrome P450 enzymes responsible for their formation. Journal of Pharmaceutical and Biomedical Analysis 28:5, pages 945-951.
Crossref
Crossref
Shufeng Zhou, Daniel Chiang, Rebecca Chin, Philip Kestell & James W Paxton. (2002) High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Journal of Chromatography B 767:1, pages 19-26.
Crossref
Crossref
Richard C. King, Cynthia Miller‐Stein, Daniel J. Magiera & John Brann. (2001) Description and validation of a staggered parallel high performance liquid chromatography system for good laboratory practice level quantitative analysis by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 16:1, pages 43-52.
Crossref
Crossref
Takahito Yamamoto, Akio Suzuki & Yoshiro Kohno. (2002) Application of Microtiter Plate Assay to Evaluate Inhibitory Effects of Various Compounds on Nine Cytochrome P450 Isoforms and to Estimate their Inhibition Patterns. Drug Metabolism and Pharmacokinetics 17:5, pages 437-448.
Crossref
Crossref
Magang Shou. 2002. Cytochrome P450 Part C. Cytochrome P450 Part C
261
276
.
A. M. Davis, J. Dixon, C. J. Logan & D. W. Payling. 2002. Pharmacokinetic Challenges in Drug Discovery. Pharmacokinetic Challenges in Drug Discovery
1
32
.
Enock Delaporte, Donald E. Slaughter, Marjorie A. Egan, Gregory J. Gatto, Albie Santos, Joanne Shelley, Elizabeth Price, Leighton Howells, Dennis C. Dean & A. David Rodrigues. (2001) The Potential for CYP2D6 Inhibition Screening Using a Novel Scintillation Proximity Assay-Based Approach. SLAS Discovery 6:4, pages 225-231.
Crossref
Crossref
A.David Rodrigues & Jiunn H Lin. (2001) Screening of drug candidates for their drug–drug interaction potential. Current Opinion in Chemical Biology 5:4, pages 396-401.
Crossref
Crossref
Hai-Zhi Bu, Kim Knuth, Lisa Magis & Philip Teitelbaum. (2001) High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy: III. Validation of a direct injection/on-line guard cartridge extraction−tandem mass spectrometry method for CYP2C19 inhibition evaluation. Journal of Pharmaceutical and Biomedical Analysis 25:3-4, pages 437-442.
Crossref
Crossref
Hai‐Zhi Bu, Lisa Magis, Kim Knuth & Philip Teitelbaum. (2001) High‐throughput cytochrome P450 (CYP) inhibition screening via a cassette probe‐dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid Communications in Mass Spectrometry 15:10, pages 741-748.
Crossref
Crossref
Ilona Kariv, Mark P. Fereshteh & Kevin R. Oldenburg. (2001) Development of a Miniaturized 384-Well High Throughput Screen for the Detection of Substrates of Cytochrome P450 2D6 and 3A4 Metabolism. SLAS Discovery 6:2, pages 91-99.
Crossref
Crossref
Hai-Zhi Bu, Lisa Magis, Kim Knuth & Philip Teitelbaum. (2001) High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy. Journal of Chromatography B: Biomedical Sciences and Applications 753:2, pages 321-326.
Crossref
Crossref
Hai-Zhi Bu, Kim Knuth, Lisa Magis & Philip Teitelbaum. (2001) High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. European Journal of Pharmaceutical Sciences 12:4, pages 447-452.
Crossref
Crossref
Larry C Wienkers. (2001) Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discovery. Journal of Pharmacological and Toxicological Methods 45:1, pages 79-84.
Crossref
Crossref
Hai-Zhi Bu, Kim Knuth, Lisa Magis & Philip Teitelbaum. (2000) High-throughput cytochrome P450 inhibition screening via cassette probe-dosing strategy. IV. Validation of a direct injection on-line guard cartridge extraction/tandem mass spectrometry method for simultaneous CYP3A4, 2D6 and 2E1 inhibition assessment. Rapid Communications in Mass Spectrometry 14:20, pages 1943-1948.
Crossref
Crossref
Hai-Zhi Bu, Lisa Magis, Kim Knuth & Philip Teitelbaum. (2000) High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy. I. Development of direct injection/on-line guard cartridge extraction/tandem mass spectrometry for the simultaneous detection of CYP probe substrates and their metabolites. Rapid Communications in Mass Spectrometry 14:17, pages 1619-1624.
Crossref
Crossref
Peter J Eddershaw, Alan P Beresford & Martin K Bayliss. (2000) ADME/PK as part of a rational approach to drug discovery. Drug Discovery Today 5:9, pages 409-414.
Crossref
Crossref
Sean Ekins, Barbara J. Ring, James Grace, Donna J. McRobie-Belle & Steven A. Wrighton. (2000) Present and future in vitro approaches for drug metabolism. Journal of Pharmacological and Toxicological Methods 44:1, pages 313-324.
Crossref
Crossref
Stephen M. FowlerRobert J. RileyMichael P. PritchardMichael J. SutcliffeThomas FriedbergC. Roland Wolf. (2000) Amino Acid 305 Determines Catalytic Center Accessibility in CYP3A4. Biochemistry 39:15, pages 4406-4414.
Crossref
Crossref
Rebecca J. Scott, Jonathan Palmer, Ivor A. S. Lewis & Stephen Pleasance. (1999) Determination of a ‘GW cocktail’ of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. Rapid Communications in Mass Spectrometry 13:23, pages 2305-2319.
Crossref
Crossref